• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by Certara Inc.

    12/16/24 4:33:11 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    cert-20231231
    00018270902023FYfalseiso4217:USDxbrli:shares00018270902023-01-012023-12-3100018270902023-06-3000018270902024-12-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    __________________________________
    FORM 10-K/A
    (Amendment No. 1)
    __________________________________
    (Mark One)
    xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2023
    OR
    oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from _____to _____
    Commission File Number: 001-39799
    __________________________________
    Certara, Inc.
    (Exact Name of Registrant as Specified in Its Charter)
    __________________________________
    Delaware82-2180925
    (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    4 Radnor Corporate Center, Suite 350
    Radnor, Pennsylvania
    19087
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (415) 237-8272
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange
    on which registered
    Common stock, par value $0.01 per shareCERTThe Nasdaq Stock Market LLC
    Securities registered pursuant to Section 12(g) of the Act: None
    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    Yes o   No x
    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    Yes o   No x
    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No o
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x   No o
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer x
    Accelerated filer o
    Non-accelerated filer o
    Smaller reporting company o
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x
    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o
    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o
    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
    The aggregate market value of the registrant’s outstanding voting common stock held by non-affiliates on June 30, 2023, determined using the per share closing price on that date on The Nasdaq Global Select Market, was $2.2 billion. There is no non-voting common equity of the registrant outstanding. Shares held by each executive officer and director and by each other person or entity deemed to be an affiliate have been excluded in such calculation. The determination of affiliate status is not necessarily a conclusive determination for other purposes.
    As of December 10, 2024, the registrant had 160,987,731 shares of common stock, par value $0.01 per share, outstanding.
    DOCUMENTS INCORPORATED BY REFERENCE

    Part III of this Form 10-K incorporates information by reference from the registrant’s definitive proxy statement that was filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report..

    EXPLANATORY NOTE
    Certara, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) on Form 10-K/A to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 29, 2024 (the “Original 10-K”) for the purpose of amending and restating Part II, Item 9A in its entirety to explicitly state management’s conclusion that internal control over financial reporting was effective as of December 31, 2023 pursuant to Item 308(a)(3) of Regulation S-K. In addition, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this Amendment. Except as expressly described herein, no other changes have been made to the Original 10-K. This Amendment speaks as of the date of the Original 10-K and does not reflect events that may have occurred after the date of the Original 10-K or modify or update any disclosures that may have been affected by subsequent events.

    Item 9A. Controls and Procedures.
    Evaluation of Disclosure Controls and Procedures
    As of the end of the period covered by this Annual Report on Form 10-K, we performed an evaluation under the supervision and with the participation of management, including our Chief Executive Officer and our Chief Financial Officer, of the design and effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934 as amended (the “Exchange Act”)). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded, as of the end of the period covered by this Annual Report that our disclosure controls and procedures were effective at the reasonable assurance level to ensure that information required to be disclosed was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and to provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
    Management’s Annual Report on Internal Control over Financial Reporting
    Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as is defined in the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external reporting



    purposes in accordance with GAAP and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and the dispositions of our assets; (2) provide reasonable assurance that our transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that our receipts and expenditures are being made only in accordance with appropriate authorizations; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.

    Our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023, based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.
    RSM US LLP, the independent registered public accounting firm that audited our consolidated financial statements as of and for the year ended December 31, 2023 included in this Report, has also audited the effectiveness of Certara’s internal control over financial reporting as of December 31, 2023. The report of RSM US LLP is included under Item 8 of this Report.
    Changes in Internal Control over Financial Reporting
    There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
    Item 15. Exhibits, Financial Statement Schedules.

    (a)The following exhibits as required by Item 601 of Regulation S-K are filed as part of this Amendment:


    Incorporated by Reference

    Exhibit NumberExhibit TitleFormFile No.ExhibitFiling Date
    2.1
    Agreement and Plan of Merger dated as of August 2, 2021, by and among Certara, Inc., Puma Merger Sub, LLC and Shareholder Representative Services LLC, as the Equityholder Representative thereunder
    8-K001-397992.18/5/2021
    3.1
    Amended and Restated Certificate of Incorporation of Certara, Inc.
    S-8333-2513684.112/15/2020
    3.2
    Amended and Restated Bylaws of Certara, Inc.
    S-8333-2513684.212/15/2020
    4.1
    Form of Stock Certificate for Common Stock
    S-1/A333-2501824.112/03/2020
    4.2
    Description of Certara, Inc.’s Securities
    10-K001-397994.23/15/2021
    10.1
    Credit Agreement, dated as of August 15, 2017, among Certara Holdings, Inc. (f/k/a EQT Avatar Holdings, Inc.), Certara Holdco, Inc., Certara USA, Inc., EQT Avatar Intermediate, Inc., Jefferies Finance LLC, as Administrative Agent and Issuing Bank, Golub Capital LLC as Issuing Bank and each lender from time to time party thereto
    S-1/A333-25018210.311/18/2020



    10.2
    First Amendment, dated as of January 24, 2018, to the Credit Agreement, among Certara Holdings, Inc. (f/k/a EQT Avatar Holdings, Inc.), Certara Holdco, Inc., Certara USA, Inc., EQT Avatar Intermediate, Inc., Jefferies Finance LLC, as Administrative Agent and Issuing Bank, Golub Capital LLC as Issuing Bank and each lender from time to time party thereto
    S-1/A333-25018210.411/18/2020
    10.3
    Second Amendment, dated as of April 3, 2018, to the Credit Agreement, among Certara Holdings, Inc. (f/k/a EQT Avatar Holdings, Inc.), Certara Holdco, Inc., Certara USA, Inc., Certara Intermediate, Inc. (f/k/a EQT Avatar Intermediate, Inc.), Jefferies Finance LLC, as Administrative Agent and Issuing Bank, Golub Capital LLC as Issuing Bank and each lender from time to time party thereto

    S-1/A333-25018210.511/18/2020
    10.4
    Third Amendment, dated as of June 17, 2021, to the Credit Agreement, among Certara Holdings, Inc., Certara Holdco, Inc., Certara USA, Inc., Certara Intermediate, Inc., Bank of America, N.A., as Administrative Agent for the lenders from time to time party thereto and collateral agent for the secured parties thereunder
    8-K001-3979910.16/22/2021
    10.5
    Loan Guaranty, dated as of August 15, 2017, by and among the Loan Guarantors, as defined therein, and Jefferies Finance LLC, as Administrative Agent
    S-1/A333-25018210.611/18/2020
    10.6
    Pledge and Security Agreement, dated as of August 15, 2017, by and among the Grantors, as defined therein, and Jefferies Finance LLC, as Agent
    S-1/A333-25018210.711/18/2020
    10.7
    Loan Agreement, dated as of July 6, 2017, between Santo Holding (Deutschland) GmbH and Certara, Inc. (f/k/a EQT Avatar Topco, Inc.)
    S-1/A333-25018210.811/18/2020
    10.8*
    Form of Indemnification Agreement between Certara, Inc. and directors and executive officers of Certara, Inc.
    S-1/A333-25018210.911/25/2020
    10.9*
    Employment Agreement, dated as of May 14, 2019, by and among EQT Avatar Parent L.P., Certara USA, Inc. and William Feehery
    S-1/A333-25018210.1011/18/2020
    10.10*
    Employment Agreement, dated September 26, 2018 between Certara UK Limited and Robert Aspbury
    10-K001-3979910.213/1/2022
    10.11*
    Employment Agreement, dated as of July 20, 2020, between Certara USA, Inc. and Leif E. Pedersen
    10-K001-3979910.123/15/2021
    10.12*
    Employment Agreement Dated as of July 11, 2014, between Certara USA, Inc. and M. Andrew Schmick.*
    10-K001-3979910.113/15/2021
    10.13*
    Employment Agreement, dated as of September 2, 2016, between D3 MEDICINE LLC, Certara USA, Inc. and Patrick Smith
    10-K001-3979910.123/1/2023
    10.14*
    Amended and Restated Employment Agreement dated as of November 7, 2023 between the Company and John E. Gallagher.*
    10-Q001-3979910.111/08/2023
    10.15
    Form of Exchange Acknowledgement and Agreement
    S-1/A333-25018210.1912/03/2020
    10.16
    Form of Stock Restriction Agreement*
    S-1/A333-25018210.2012/03/2020
    10.17
    Form of Restricted Stock Unit Grant and Award Agreement (Certara, Inc. 2020 Incentive Plan)
    10-K001-3979910.143/15/2021
    10.18
    Certara, Inc. 2020 Incentive Plan
    S-1/A333-25018210.1811/25/2020
    10.19
    Form of 2022 Performance Stock Unit Grant Notice and Agreement for Certara, Inc. 2020 Incentive Plan
    10-Q001-3979910.15/7/2021



    10.20
    2022 Amended and Restated Form of PSU Grant Award Agreement**
    10-Q333-25018210.25/8/2023
    10.21
    Form of PSU Grant and Award Agreement (2023 Grants) **


    10-Q001-3979910.35/8/2023
    10.22
    Certara, Inc. 2020 Employee Stock Purchase Plan
    S-1/A333-25018210.2111/25/2020
    10.23
    Certara, Inc. Directors Deferral Plan*
    10-K001-3979910.183/15/2021
    10.24
    Letter Agreement Dated as of November 3, 2022, by and among Certara, Inc. and Arsenal Saturn Holdings LP.
    8-K001-3979910.111/7/2022
    10.25
    Stockholders Agreement, dated as of November 3, 2022, by and among Certara, Inc. and the other parties thereto
    8-K001-3979910.211/7/2022
    10.26
    Registration Rights Agreement, dated as of November 3, 2022, by and among Certara, Inc. and the other parties thereto
    8-K001-3979910.311/7/2022
    10.27
    LIBOR Transition Amendment.
    10-Q001-3979910.18/9/2023
    10.28#
    Clawback Policy Effective December 1, 2023*
    16.1
    Letter from CohnReznick LLP to the Securities and Exchange Commission, dated March 30, 2022
    8-K001-3979916.13/30/2022
    21.1#
    Subsidiaries of the Registrant
    23.1#
    Consent of CohnReznick LLP
    23.2#
    Consent of RSM US LLP
    24.1#
    Power of Attorney (included in the signature page to this Annual Report)
    31.1^
    Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    31.2^
    Certification of Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    32.1^
    Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
    32.2^
    Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
    101.INSXBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
    101.SCHXBRL Taxonomy Extension Schema Document
    101.CALXBRL Taxonomy Extension Calculation Linkbase Document
    101.DEFXBRL Taxonomy Extension Definition Linkbase Document
    101.LABXBRL Taxonomy Extension Label Linkbase Document
    101.PREXBRL Taxonomy Extension Presentation Linkbase Document
    104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)


    * Management contract or compensatory plan or arrangement.

    ** Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished.

    # Previously filed with the Original 10-K.




    ^ Filed herewith.

    + This certification is deemed not filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.










    Signatures
    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.
    CERTARA, INC.
    Date: December 16, 2024
    By:/s/ WILLIAM F. FEEHERY
    Name:William F. Feehery
    Title:Chief Executive Officer
    (Principal Executive Officer)



    Get the next $CERT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    1/6/2026$13.00Market Perform → Outperform
    Leerink Partners
    11/21/2025$10.00Buy
    Rothschild & Co Redburn
    11/13/2025$9.00Market Perform
    BMO Capital Markets
    9/29/2025$16.00Buy
    Craig Hallum
    7/3/2025$16.00Equal-Weight
    Morgan Stanley
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    More analyst ratings

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025

    RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medic

    1/29/26 8:30:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave

    Issued on behalf of Aleen Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error approaches to computational creation of biological solutions[1]. The generative AI healthcare market is projected to surge from $2.64B in 2025 to $39.70B by 2034, reflecting the technology's expansion from simple data analysis to active creation and interpretation of therapeutic compounds[2]. This Platform-First revolution is extending rapidly into c

    12/12/25 10:15:00 AM ET
    $ABSI
    $AMZN
    $CERT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Catalog/Specialty Distribution
    Consumer Discretionary

    Healthcare AI Exits Pilot Phase, Enters Production Deployment

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems[1]. The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035[2]. Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns

    12/12/25 9:59:27 AM ET
    $CERT
    $CTSH
    $DOCS
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Medical Specialities

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Certara upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Certara from Market Perform to Outperform and set a new price target of $13.00

    1/6/26 8:38:03 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Rothschild & Co Redburn initiated coverage on Certara with a new price target

    Rothschild & Co Redburn initiated coverage of Certara with a rating of Buy and set a new price target of $10.00

    11/21/25 8:08:25 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    BMO Capital Markets initiated coverage on Certara with a new price target

    BMO Capital Markets initiated coverage of Certara with a rating of Market Perform and set a new price target of $9.00

    11/13/25 9:12:36 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    SEC Filings

    View All

    Certara Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Certara, Inc. (0001827090) (Filer)

    12/11/25 6:00:54 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.

    SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)

    11/25/25 3:36:45 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SCHEDULE 13G filed by Certara Inc.

    SCHEDULE 13G - Certara, Inc. (0001827090) (Subject)

    11/13/25 5:32:49 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Resnick Jon Matthew

    3 - Certara, Inc. (0001827090) (Issuer)

    1/12/26 4:59:18 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E sold $559,366 worth of shares (51,224 units at $10.92), decreasing direct ownership by 41% to 73,979 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    9/11/25 4:47:56 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Certara Inc.

    SC 13G - Certara, Inc. (0001827090) (Subject)

    11/14/24 8:38:56 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Certara Inc.

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    10/4/24 10:25:50 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    2/13/24 5:01:03 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    View All

    Certara Appoints Jon Resnick as Chief Executive Officer

    Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g

    12/11/25 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

    RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data

    7/31/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    3/5/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Financials

    Live finance-specific insights

    View All

    Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025

    RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medic

    1/29/26 8:30:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Reports Third Quarter 2025 Financial Results

    RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 million, compared to $58.9 million in the third quarter of 2024, representing growth of 3%. Net income was $1.5 million, compared to a net loss of $1.4 million in the third quarter of 2024, representing

    11/6/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

    RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulation softw

    10/10/25 8:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology